Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non–Small Cell Lung Cancer - Journal of Thoracic Oncology
Alectinib for treatment of ALK-positive non-small-cell lung cancer | Future Oncology
Overall Survival Data: Primary & Exploratory 5-Year Landmark Analysis - ALECENSA® (alectinib)
Progression-Free and Overall Survival of Patients With ALK Rearrangement–Positive Non–Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib - Clinical Lung Cancer
Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer - Lung Cancer
Potent treatment options in ALK– and MET-positive disease - memoinOncology
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study - Annals of Oncology
Progression-free survival by IRC Shown is the Kaplan-Meier curve for... | Download Scientific Diagram
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
New standards of care for ALK-positive disease - memoinOncology
Cancers | Free Full-Text | Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis | HTML
Kaplan-Meier analyses of survival in patients treated with alectinib... | Download Scientific Diagram
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
Supplemental Materials for Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial - The Lancet Oncology
Alectinib Yields Better Overall Survival Than Ceritinib in ALK-Positive Non–Small Cell Lung Cancer
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - Annals of Oncology
Roche - European Commission approves Roche's Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer
Progression-free survival of patients with ALK-positive NSCLC | Download Scientific Diagram
YIR On Demand Lung Benjamin Levy, MD Assistant Professor - ppt download
The efficacy and safety of ALK inhibitors in the treatment of ALK‐positive non‐small cell lung cancer: A network meta‐analysis - Fan - 2018 - Cancer Medicine - Wiley Online Library
First-Line PFS - ALECENSA® (alectinib)
EGFR- and ALK-targeted treatment: present and future - memoinOncology
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer | NEJM
How the CROWN Study Affects Treatment of Patients With ALK-Positive Metastatic Non–Small Cell Lung Cancer
First-Line PFS - ALECENSA® (alectinib)
ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials - Journal of Thoracic Oncology
JALEX Phase III Trial of Alectinib versus Crizotinib
